Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
$225.87M
Dr. Jay R. Luly Ph.D.
160.00
Watertown, MA
Mar 21, 2013
-1.96
$-5.45
0.62
4.92
-160.27%
-2.00
-0.13
1.55
3.20
4.92
-28.92%
-63.75%
Similar stocks (13)
Revolution Medicines, Inc.
RVMD
Crinetics Pharmaceuticals, Inc.
CRNX
Edgewise Therapeutics, Inc.
EWTX
Cullinan Oncology, Inc.
CGEM
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
C4 Therapeutics, Inc.
CCCC
Lyell Immunopharma, Inc.
LYEL
Inhibrx, Inc.
INBX
Century Therapeutics, Inc.
IPSC
Werewolf Therapeutics, Inc.
HOWL
Ikena Oncology, Inc.
IKNA
Kronos Bio, Inc.
KRON
ETF Exposure (17)
ETFMG Treatments, Testing and Advancements ETF
GERM
0.62%
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.397%
iShares Micro-Cap ETF
IWC
0.05051%
iShares Russell 2000 Value ETF
IWN
0.01506%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.013%
iShares Russell 2000 ETF
IWM
0.00758%
Dimensional U.S. Small Cap ETF
DFAS
0.00605255%
Schwab U.S. Small-Cap ETF
SCHA
0.0056361499%
Dimensional U.S. Targeted Value ETF
DFAT
0.00230132%
ALPS Medical Breakthroughs ETF
SBIO
0.0014%
ProShares Hedge Replication ETF
HDG
0.001198825353581786%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
6.8e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
5.228300000000001e-4%
Schwab U.S. Broad Market ETF
SCHB
3.733422e-4%
iShares Russell 3000 ETF
IWV
3.4e-4%
Dimensional U.S. Equity ETF
DFUS
2.0818e-4%
Dimensional US Core Equity Market ETF
DFAU
1.5187e-4%
Similar stocks (13)
Revolution Medicines, Inc.
RVMD
Crinetics Pharmaceuticals, Inc.
CRNX
Edgewise Therapeutics, Inc.
EWTX
Cullinan Oncology, Inc.
CGEM
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
C4 Therapeutics, Inc.
CCCC
Lyell Immunopharma, Inc.
LYEL
Inhibrx, Inc.
INBX
Century Therapeutics, Inc.
IPSC
Werewolf Therapeutics, Inc.
HOWL
Ikena Oncology, Inc.
IKNA
Kronos Bio, Inc.
KRON
ETF Exposure (17)
ETFMG Treatments, Testing and Advancements ETF
GERM
0.62%
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.397%
iShares Micro-Cap ETF
IWC
0.05051%
iShares Russell 2000 Value ETF
IWN
0.01506%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.013%
iShares Russell 2000 ETF
IWM
0.00758%
Dimensional U.S. Small Cap ETF
DFAS
0.00605255%
Schwab U.S. Small-Cap ETF
SCHA
0.0056361499%
Dimensional U.S. Targeted Value ETF
DFAT
0.00230132%
ALPS Medical Breakthroughs ETF
SBIO
0.0014%
ProShares Hedge Replication ETF
HDG
0.001198825353581786%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
6.8e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
5.228300000000001e-4%
Schwab U.S. Broad Market ETF
SCHB
3.733422e-4%
iShares Russell 3000 ETF
IWV
3.4e-4%
Dimensional U.S. Equity ETF
DFUS
2.0818e-4%
Dimensional US Core Equity Market ETF
DFAU
1.5187e-4%